Potentially repurposing adamantanes for COVID-19.
Identifieur interne : 000450 ( PubMed/Curation ); précédent : 000449; suivant : 000451Potentially repurposing adamantanes for COVID-19.
Auteurs : Nevio Cimolai [Canada]Source :
- Journal of medical virology [ 1096-9071 ] ; 2020.
DOI: 10.1002/jmv.25752
PubMed: 32176361
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000450
Links to Exploration step
pubmed:32176361Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Potentially repurposing adamantanes for COVID-19.</title><author><name sortKey="Cimolai, Nevio" sort="Cimolai, Nevio" uniqKey="Cimolai N" first="Nevio" last="Cimolai">Nevio Cimolai</name><affiliation wicri:level="1"><nlm:affiliation>Faculty of Medicine, Children's and Women's Health Centre of British Columbia, The University of British Columbia, Vancouver, British Columbia, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Faculty of Medicine, Children's and Women's Health Centre of British Columbia, The University of British Columbia, Vancouver, British Columbia</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32176361</idno><idno type="pmid">32176361</idno><idno type="doi">10.1002/jmv.25752</idno><idno type="wicri:Area/PubMed/Corpus">000450</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000450</idno><idno type="wicri:Area/PubMed/Curation">000450</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000450</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Potentially repurposing adamantanes for COVID-19.</title><author><name sortKey="Cimolai, Nevio" sort="Cimolai, Nevio" uniqKey="Cimolai N" first="Nevio" last="Cimolai">Nevio Cimolai</name><affiliation wicri:level="1"><nlm:affiliation>Faculty of Medicine, Children's and Women's Health Centre of British Columbia, The University of British Columbia, Vancouver, British Columbia, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Faculty of Medicine, Children's and Women's Health Centre of British Columbia, The University of British Columbia, Vancouver, British Columbia</wicri:regionArea></affiliation></author></analytic><series><title level="j">Journal of medical virology</title><idno type="eISSN">1096-9071</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader></TEI><pubmed><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">32176361</PMID><DateRevised><Year>2020</Year><Month>03</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1096-9071</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2020</Year><Month>Mar</Month><Day>16</Day></PubDate></JournalIssue><Title>Journal of medical virology</Title><ISOAbbreviation>J. Med. Virol.</ISOAbbreviation></Journal><ArticleTitle>Potentially repurposing adamantanes for COVID-19.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1002/jmv.25752</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cimolai</LastName><ForeName>Nevio</ForeName><Initials>N</Initials><Identifier Source="ORCID">http://orcid.org/0000-0003-2743-0556</Identifier><AffiliationInfo><Affiliation>Faculty of Medicine, Children's and Women's Health Centre of British Columbia, The University of British Columbia, Vancouver, British Columbia, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>03</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Med Virol</MedlineTA><NlmUniqueID>7705876</NlmUniqueID><ISSNLinking>0146-6615</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>03</Month><Day>05</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>03</Month><Day>06</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>3</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>3</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>3</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32176361</ArticleId><ArticleId IdType="doi">10.1002/jmv.25752</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Zhang Q, Wang Y, Qi C, Shen L, Li J. Clinical trial analysis of 2019-nCoV therapy registered in China [published online ahead of print February 28, 2020]. J Med Virol. 2020. https://doi.org/10.1002/jmv.25733</Citation></Reference><Reference><Citation>Gao J, Tian Z, Yang X. Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies [published online ahead of print February 19, 2020]. Biosci Trends. 2020. https://doi.org/10.5582/bst.2020.01047</Citation></Reference><Reference><Citation>Payne HR, Storz J, Henk WG. Initial events in bovine coronavirus infection: analysis through immunogold probes and lysomotropic inhibitors. Arch Virol. 1990;114(3-4):175-189.</Citation></Reference><Reference><Citation>Keyaerts E, Vijgen L, Maes P, Neyts J, Van Ranst M. In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine. Biochem Biophys Res Commun. 2004;323(1):264-268.</Citation></Reference><Reference><Citation>Takano T, Katoh Y, Doki T, Hohdatsu T. Effect of chloroquine on feline infectious peritonitis virus infection in vitro and in vivo. Antiviral Res. 2013;99(2):100-107.</Citation></Reference><Reference><Citation>Kono M, Tatsumi K, Imai AM, Saito K, Kuriyama T, Shirasawa H. Inhibition of human coronavirus 229E infection in human epithelial lung cells (L132) by chloroquine: involvement of p38 MAPK and ERK. Antiviral Res. 2008;77(2):150-152.</Citation></Reference><Reference><Citation>Shen L, Yang Y, Ye F, et al. Safe and sensitive antiviral screening platform based on recombinant human coronavirus OC43 expressing the luciferase reporter gene. Antimicrob Agents Chemother. 2016;60(9):5492-5503.</Citation></Reference><Reference><Citation>Mathur A, Beare AS, Reed SE. In vitro antiviral activity and preliminary clinical trials of a new adamantane compound. Antimicrob Agents Chemother. 1973;4(4):421-426.</Citation></Reference><Reference><Citation>Leibowitz JL, Reneker SJ. The effect of amantadine on mouse hepatitis virus replication. Adv Exp Med Biol. 1993;342:117-122.</Citation></Reference><Reference><Citation>Chen F, Chan KH, Jiang Y, et al. In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds. J Clin Virol. 2004;31(1):69-75.</Citation></Reference><Reference><Citation>Brison E, Jacomy H, Desforges M, Talbot PJ. Novel treatment with neuroprotective and antiviral properties against a neuroinvasive human respiratory virus. J Virol. 2014;88(3):1548-1563.</Citation></Reference><Reference><Citation>Tanner JA, Zheng B-J, Zhou J, et al. The adamantine-derived bananins are potent inhibitors of the helicase activities and replication of SARS coronavirus. Chem Biol. 2005;12(3):303-311.</Citation></Reference><Reference><Citation>Tan ELC, Ooi EE, Lin C-Y, et al. Inhibition of SARS coronavirus infection in vitro with clinically approved antiviral drugs. Emerg Infect Dis. 2004;10(4):581-586.</Citation></Reference><Reference><Citation>Takano T, Nakano K, Doki T, Hohdatsu T. Differential effects of viroporin inhibitors against feline infectious peritonitis virus serotypes I and II. Arch Virol. 2015;160(5):1163-1170.</Citation></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/CovidV2/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000450 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000450 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= CovidV2
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:32176361
|texte= Potentially repurposing adamantanes for COVID-19.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:32176361" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a CovidV2
| This area was generated with Dilib version V0.6.33. |  |